Recent research from Queen Mary University of London (QMUL) has shed new light on a critical issue in prostate cancer diagnosis: the sharp increase in overdiagnosis as men age. Prostate cancer overdiagnosis occurs when screening detects cancers that would never have caused symptoms or harm during a person's lifetime, leading to unnecessary treatments with potential side effects like incontinence and impotence. This study, published in the International Journal of Cancer, analyzed data from the UK Cluster Randomised Trial of PSA Testing for Prostate Cancer (CAP trial), involving over 400,000 men aged 50 to 69. The findings reveal that while screening benefits younger men, the risks skyrocket for those over 70, prompting calls for more targeted prostate cancer screening strategies in the UK.
The CAP trial, one of the largest prostate cancer screening studies in the UK, compared a single invitation for prostate-specific antigen (PSA) testing against standard care without routine screening. Initial results showed no significant mortality benefit after 10 years, but longer follow-up has provided deeper insights into detection rates and overdiagnosis. QMUL's Wolfson Institute of Population Health led the analysis, demonstrating how competing mortality—deaths from other causes—plays a pivotal role in interpreting screening outcomes.
Understanding Overdiagnosis in Prostate Cancer Screening
Prostate-specific antigen (PSA) testing measures a protein produced by prostate cells, elevated levels of which can signal cancer. However, PSA is not specific to cancer; benign conditions like enlarged prostates also raise levels. In the UK, where prostate cancer is the most common cancer among men with over 56,000 new diagnoses annually and around 12,000 deaths, opportunistic PSA testing is available for men over 50 upon request after discussing risks and benefits. No national screening program exists due to concerns over overdiagnosis and overtreatment.
Overdiagnosis leads to overtreatment because many prostate cancers are slow-growing and indolent. Treatments such as surgery or radiation carry risks including erectile dysfunction (up to 50% of cases), urinary incontinence (10-20%), and bowel issues. The QMUL study quantifies this risk by age, showing that 11.7% of screen-detected cancers would not surface clinically within 15 years without screening. Adjusting for competing mortality—heart disease, strokes, and other age-related conditions—the true overdiagnosis probability jumps dramatically with age.
Key Statistics: Age-Stratified Overdiagnosis Risks
The study's results are striking. For men diagnosed at age 50, the overdiagnosis risk is 16%—meaning one in six detected cancers might never have progressed harmfully. This rises to 32% at age 70 and a staggering 58% at age 80. These figures account for the fact that older men are more likely to die from other causes before prostate cancer becomes lethal.
- Men aged 50-59: Low overdiagnosis (around 16-20%), higher potential benefit from early detection.
- Men aged 60-69: Moderate risk (25-35%), balanced approach needed.
- Men aged 70+: High overdiagnosis (over 40%), screening often futile.
These insights come from modeling lead times—the period a cancer would remain undetected without screening—against UK life tables for competing mortality. Lead researcher Dr. Adam Brentnall emphasized, "Prostate cancer screening and PSA testing appear more appropriate for men in their 50s and early 60s, where overdiagnosis risk is relatively low." For more on the methodology, see the full study here.
The CAP Trial: Foundation of the Research
Launched in 2001-2009 across 573 primary care practices, the CAP trial randomized over 419,000 men to receive a single PSA invitation or not. About 35% attended screening, detecting 6.6% with elevated PSA, leading to biopsies and diagnoses. Long-term follow-up through cancer registries and mortality data enabled precise overdiagnosis estimates. QMUL's analysis builds on prior CAP findings, which at 15 years showed a modest mortality reduction but highlighted detection of low-risk cancers.
This trial underscores UK universities' role in global health research. Queen Mary, part of the Barts Cancer Institute network, exemplifies how higher education institutions drive evidence-based policy through rigorous trials.
Implications for UK Screening Policies
The UK National Screening Committee (UK NSC) currently does not recommend routine PSA screening due to harms outweighing benefits in population-wide application. However, ongoing trials like TRANSFORM—a £42 million initiative led by QMUL's Professor Rhian Gabe—aim to refine strategies using MRI and biomarkers to minimize overdiagnosis. TRANSFORM, funded by Prostate Cancer UK, tests multi-stage screening in 350,000 men, potentially halving unnecessary biopsies.
Dr. Brentnall suggests revising opportunistic testing: "Policies should discourage PSA testing in men over 70, as mortality reduction is unlikely." This aligns with NICE guidelines advising shared decision-making, emphasizing age and comorbidities. For context on UK trends, incidence rose 14% projected to 2038-2040, per Cancer Research UK.
Stakeholder Perspectives: Experts Weigh In
Professor Stephen Duffy, QMUL statistician, notes, "Competing mortality makes screening less effective in older men; resources are better directed to younger cohorts." Prostate Cancer UK welcomes the data, advocating targeted programs for high-risk groups like BRCA carriers (screen from 45-61).
Urologists highlight MRI's role: Pre-biopsy MRI reduces overdiagnosis by 28% (PROMIS trial, UCL). UK universities like Oxford and Cambridge contribute via genomic risk scores to personalize screening.
Patient advocates stress informed consent: Tools like Prostate Cancer UK's Risk Checker help men assess personal risks.
Challenges in Balancing Benefits and Harms
PSA screening reduces mortality by 13-20% in trials like ERSPC, but absolute benefit is small (1 death prevented per 1,000 screened). Harms include 50 unnecessary biopsies per life saved, psychological anxiety, and treatment side effects. In older men, benefits diminish as competing risks dominate—e.g., 80-year-olds have <10% lifetime prostate cancer mortality risk.
- Benefits: Early detection of aggressive cancers, improved survival (5-year rate 90% localized vs 30% advanced).
- Risks: Overdiagnosis (20-50%), overtreatment, costs (£300m/year NHS PSA tests).
Read detailed analysis from News-Medical here.
Queen Mary University London's Research Leadership
QMUL's Wolfson Institute excels in population health, with expertise in screening trials. Past contributions include Prolaris genomic test validation. This overdiagnosis study reinforces their impact, informing policy amid rising incidence (64,000 cases 2022). As UK unis face funding pressures, such research positions QMUL as a hub for medical innovation, training future oncologists and epidemiologists.
Future Outlook: Personalized and Risk-Stratified Screening
Emerging tools like polygenic risk scores (PRS) could halve overdiagnosis (QMUL collaborations). Trials like REATTEMPT explore MRI-first pathways. By 2030, AI-enhanced PSA (e.g., London-based startups) may optimize targeting. UK higher ed must invest in interdisciplinary training—genomics, AI, ethics—to lead global advances.
Actionable insights: Men 50-64 discuss PSA with GPs; over 70 prioritize comorbidities. Universities foster public engagement via open days on cancer research.
Photo by Vitaly Gariev on Unsplash
Broader Impacts on UK Higher Education and Medical Training
This research highlights UK unis' pivotal role in addressing health disparities. QMUL's findings influence curricula at medical schools like Barts, emphasizing evidence-based screening. Amid postdoc shortages, it underscores need for research funding—STFC reversals offer hope. Collaborative networks like Russell Group drive trials, training clinician-scientists.
